Regenerative Medical Solutions Inc.
Park Ridge, IL
- UEI
- WK5KJPECBBA3
- CAGE
- 6S0V4
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1116 Vine Ave, Park Ridge, IL 60068, USA
- Website
- regenmedsolutions.com
- Founded
- 2012
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Aleutian Therapeutics, Inc. | Los Angeles, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Minutia Inc. | Oakland, CA | — |
| (A Development Stage Company) | — | 813990 Other Similar Organizations (except Business, Professional, Labor, and Political Organizations) |
| Prodo Laboratories, Inc. | Aliso Viejo, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Stembiosys Inc. | San Antonio, TX | 238990 All Other Specialty Trade Contractors |
About the company
Regenerative Medical Solutions Inc. (RMS) is a for-profit corporate entity registered in SAM.gov since June 2012, located in Park Ridge, Illinois. The company appears to be focused on developing innovative cell-based therapies for diabetes, with a specific emphasis on stem cell research and regenerative medical technologies. RMS has developed proprietary protocols for converting induced pluripotent stem cells (iPSC) into islet-like clusters (ILC) containing insulin-producing beta-like cells, representing a cutting-edge approach to potential diabetes treatment.
RMS has been awarded multiple federal grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to advance its research into safer and more effective diabetes therapies. The company's primary research objectives include developing cell-based diabetes treatments that can be manufactured in large quantities without requiring lifelong immunosuppression. Specifically, RMS has collaborated with partners like the Diabetes Research Institute at the University of Miami, the University of Wisconsin-Madison, and Pluristyx to conduct advanced research. Their projects involve creating innovative approaches such as using Fas ligand conjugated microparticles to induce localized immune tolerance and developing genetically engineered stem cell lines with built-in safety mechanisms like suicide gene technology to prevent uncontrolled cell proliferation. The grants, awarded in 2022, are project-based research awards with completion dates ranging from 2024 to 2027, focusing on creating novel therapeutic approaches that could potentially revolutionize diabetes treatment by addressing current limitations in cell-based therapies.
Quick answers
Is Regenerative Medical Solutions Inc. registered in SAM.gov?
Yes. Regenerative Medical Solutions Inc.'s SAM.gov registration is active through November 11, 2026.
What is Regenerative Medical Solutions Inc.'s most recent federal award?
Regenerative Medical Solutions Inc.'s most recent federal grant award is Evaluation of a beta cell replacement therapy combined product that avoids the need for immunosuppression via localized… (R41DK135191), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on September 23, 2022.
On GovTribe
See Regenerative Medical Solutions Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors